

Rare – but more common and more challenging than you think, pp. 16-19

Annalisa Trama, Roberto Mazza and Gemma Gatta
Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano

1. Gatta, G., van der Zwan, J.M., Casali Paolo, G., et al., *Rare cancers are not so rare: The rare cancer burden in Europe*. Eur J Cancer, 2011 **47**(17): 2493-511.
2. Surveillance of rare cancers in Europe. www.rarecare.eu.
3. European Parliament and Council of the European Communities (1999). Decision No. 1295/1999/EC of the European Parliament and of the Council of 29 April 1999 adopting a programme of Community action on rare diseases within the framework for action in the field of public health (1999-2003).
4. Call to Action Against Rare Cancers. European Action Against Rare Cancers. www.rarecancerseurope.org.
5. Craine, S., and Geissler, J., Realising the vision of equity: the optimal care and treatment of rare cancers in Europe. European Cancer Patient Coalition position paper, 28 February 2009.
6. Rare Diseases: understanding this Public Health Priority. Eurordis, November 2005. www.eurordis.org/IMG/pdf/princeps_document-EN.pdf.
7. Terracini, B., Coebergh, J.W., Gatta G., et al., *Childhood cancer survival in Europe: an overview*. Eur J Cancer, 2001, **37**:810-6.
8. Gatta, G., Zigon, G., Capocaccia, R., et al., *Survival of European children and young adults with cancer diagnosed 1995-2002*. Eur J Cancer, 2009, **45**:992-1005.

Researching rare cancers: challenges and solutions, pp. 20-21

Jean-Yves Blay
Centre Léon Bérard, 28, rue Laennec 69008 Lyon, France

References:

1. Improving care for rare cancers in Europe: a set of multidisciplinary recommendations.
http://www.esmo.org/fileadmin/media/pdf/policies/ESMO_Rare_Cancers_REC_OMMENDATIONS.pdf
2. Clark, M.A., Fisher, C., Judson, I., and Thomas, J.M., *Soft-tissue sarcomas in adults*. N Engl J Med. 2005, **353**:701-11.
3. Helman, L.J., and Meltzer, P., *Mechanisms of sarcoma development*. Nat Rev Cancer, 2003, **3**:685-94.

Regulating orphan drugs in Europe, pp. 24-26

Kerstin Westermark
Senior expert, Medical Products Agency, Sweden

References:

1. Official Journal of the European Communities. Regulation No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (ec.europa.eu/health/files/eudralex/vol-1/reg.../reg_2000_141_en.pdf) and regulation No. 847/2000 of 27 April 2000 (ec.europa.eu/health/files/eudralex/vol-1/reg.../reg_2000_847_en.pdf).
2. Westermark, K., et al., *European regulation on orphan medicinal products: 10 years of experience and future perspectives*. Nat Rev Drug Discov, 2011, **10**(5):341-9.
3. European Union Health Programme. Creation of a process for the exchange of knowledge between Member States and European authorities on the scientific assessment of the clinical added value for orphan medicines. Reference EAHC/2010/Health/05.
http://ec.europa.eu/eahc/documents/news/CAVOD_Final%20Report_vf_corrected_281011.pdf